Although we cannot clearly distinguish which isoform, PAK1 and/or PAK2, is responsible for the observed effect, PAK1/2 may be taken into consideration as targets for the treatment of CML. Here, PAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.